Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.

IF 1.7 3区 医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Pharmacogenetics and genomics Pub Date : 2022-04-01 DOI:10.1097/FPC.0000000000000455
Tien M Truong, Jeffrey L Apfelbaum, Emily Schierer, Keith Danahey, Brittany A Borden, Theodore Karrison, Sajid Shahul, Magdalena Anitescu, Rebecca Gerlach, Randall W Knoebel, David O Meltzer, Mark J Ratain, Peter H O'Donnell
{"title":"Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.","authors":"Tien M Truong,&nbsp;Jeffrey L Apfelbaum,&nbsp;Emily Schierer,&nbsp;Keith Danahey,&nbsp;Brittany A Borden,&nbsp;Theodore Karrison,&nbsp;Sajid Shahul,&nbsp;Magdalena Anitescu,&nbsp;Rebecca Gerlach,&nbsp;Randall W Knoebel,&nbsp;David O Meltzer,&nbsp;Mark J Ratain,&nbsp;Peter H O'Donnell","doi":"10.1097/FPC.0000000000000455","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions of anesthesiologists, critical care and pain medicine providers would uncover unique considerations for future implementation within perioperative care.</p><p><strong>Methods: </strong>A survey (multiple choice and Likert-scale) was administered to providers within our Department of Anesthesia and Critical Care prior to initiation of a department-wide prospective pharmacogenomics implementation program. The survey addressed knowledge, perceptions, experiences, resources and barriers.</p><p><strong>Results: </strong>Of 153 providers contacted, 149 (97%) completed the survey. Almost all providers (92%) said that genetic results influence drug therapy, and few (22%) were skeptical about the usefulness of pharmacogenomics. Despite this enthusiasm, 87% said their awareness about pharmacogenomic information is lacking. Feeling well-informed about pharmacogenomics was directly related to years in practice/experience: only 38% of trainees reported being well-informed, compared to 46% of those with 1-10 years of experience, and nearly two-thirds with 11+ years (P < 0.05). Regarding barriers, providers reported uncertainty about availability of testing, turnaround time and whether testing is worth financial costs.</p><p><strong>Conclusions: </strong>Anesthesiology, critical care and pain medicine providers are optimistic about the potential clinical utility of pharmacogenomics, but are uncertain about practical aspects of testing and desire clear guidelines on the use of results. These findings may inform future institutional efforts toward greater integration of genomic results to improve medication-related outcomes.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":"32 3","pages":"79-86"},"PeriodicalIF":1.7000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940738/pdf/nihms-1728765.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenetics and genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FPC.0000000000000455","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions of anesthesiologists, critical care and pain medicine providers would uncover unique considerations for future implementation within perioperative care.

Methods: A survey (multiple choice and Likert-scale) was administered to providers within our Department of Anesthesia and Critical Care prior to initiation of a department-wide prospective pharmacogenomics implementation program. The survey addressed knowledge, perceptions, experiences, resources and barriers.

Results: Of 153 providers contacted, 149 (97%) completed the survey. Almost all providers (92%) said that genetic results influence drug therapy, and few (22%) were skeptical about the usefulness of pharmacogenomics. Despite this enthusiasm, 87% said their awareness about pharmacogenomic information is lacking. Feeling well-informed about pharmacogenomics was directly related to years in practice/experience: only 38% of trainees reported being well-informed, compared to 46% of those with 1-10 years of experience, and nearly two-thirds with 11+ years (P < 0.05). Regarding barriers, providers reported uncertainty about availability of testing, turnaround time and whether testing is worth financial costs.

Conclusions: Anesthesiology, critical care and pain medicine providers are optimistic about the potential clinical utility of pharmacogenomics, but are uncertain about practical aspects of testing and desire clear guidelines on the use of results. These findings may inform future institutional efforts toward greater integration of genomic results to improve medication-related outcomes.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
麻醉提供者作为利益相关者在围手术期护理中采用药物基因组学信息。
目的:药物基因组学与临床护理的整合正在多个学科中进行研究。我们假设,了解麻醉师、重症监护和止痛药提供者的态度和看法,将为未来围手术期护理的实施提供独特的考虑因素。方法:在开始全科范围的前瞻性药物基因组学实施计划之前,对我们麻醉和重症监护科的提供者进行了一项调查(多项选择和李克特量表)。调查涉及知识、观念、经验、资源和障碍。结果:在联系的153家提供者中,149家(97%)完成了调查。几乎所有的提供者(92%)都表示基因结果会影响药物治疗,很少有人(22%)对药物基因组学的有用性持怀疑态度。尽管有这种热情,87%的人表示他们对药物基因组学信息缺乏认识。感觉对药物基因组学的了解程度与实践/经验的年数直接相关:只有38%的学员报告对药物基因组学的了解程度,相比之下,1-10年经验的学员占46%,11年以上经验的学员占近三分之二(P < 0.05)。关于障碍,供应商报告了测试的可用性、周转时间和测试是否值得花费财务成本的不确定性。结论:麻醉学、重症监护和止痛药提供者对药物基因组学的潜在临床应用持乐观态度,但对测试的实际方面不确定,并希望对结果的使用有明确的指导方针。这些发现可能为未来的机构努力提供信息,以更好地整合基因组结果,以改善与药物相关的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacogenetics and genomics
Pharmacogenetics and genomics 医学-生物工程与应用微生物
CiteScore
3.20
自引率
3.80%
发文量
47
审稿时长
3 months
期刊介绍: ​​​​Pharmacogenetics and Genomics is devoted to the rapid publication of research papers, brief review articles and short communications on genetic determinants in response to drugs and other chemicals in humans and animals. The Journal brings together papers from the entire spectrum of biomedical research and science, including biochemistry, bioinformatics, clinical pharmacology, clinical pharmacy, epidemiology, genetics, genomics, molecular biology, pharmacology, pharmaceutical sciences, and toxicology. Under a single cover, the Journal provides a forum for all aspects of the genetics and genomics of host response to exogenous chemicals: from the gene to the clinic.
期刊最新文献
Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Updated analysis of the pharmacogenomics of pediatric bronchodilator response. Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma. Differential distribution of NAT2 polymorphisms and NAT2 acetylator phenotypes among indigenous populations of the Brazilian Amazon.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1